Non-small cell lung cancer patients are already tested for EGFR and p53 mutations, but there is currently no standard test to detect the presence of whole genome doubling.

City of Hope co-led the first study to demonstrate that characterizing genetic material near chromosomes forecasts how mutated, cancer-causing genes reengineer DNA and alter the tumor microenvironment ...

We've shown why having a p53 mutation is associated with worse survival in patients with non-smoking related lung cancer, which is the combination of EGFR and p53 mutations enabling genome doubling.

City of Hope researchers have co-led the first study to demonstrate that characterizing genetic material near chromosomes forecasts how mutated, cancer-causing genes reengineer DNA and alter the tumor ...

You’ll have more treatment options for EGFR-positive non-small-cell lung cancer (NSCLC) now than ever before. But doctors are still testing new treatments and combinations in clinical trials.

Median baseline eGFR measured by Cockcroft-Gault was 89 mL/min/1.73 m² and 82 mL/min/1.73 m² with eGFR-CR-Cys. Average patient age was 66, 66% were female, and 83% were white.

EGFR mutation is a type of DNA mistake that causes cancer cells to grow and divide faster, This form of lung cancer largely affects young people and Asian women. Learn more.

Please use one of the following formats to cite this article in your essay, paper or report: APA. Chaphalkar, Sushama R.. (2024, November 14). Scientists map cancer mutations in EGFR gene ...

Over a 20-year period, 1.12% of patients who were treated with EGFR inhibitors developed new-onset keratitis compared with 0.74% of those who did not take these drugs (HR 1.520, 95% CI 1.339-1.725 ...

On the basis of data from 227,643 patients in Sweden, the rescaling factor for cystatin C was estimated at 0.83 for men and women younger than 50 years of age and 0.83+0.005×(age–50) for those ...

A review published in PLoS One found that removal of race adjustments in measurement of estimated glomerular filtration rate (eGFR) improved bias, accuracy, and precision in eGFR equations ...